Skip to content

Transcranial Magnetic Stimulation and Constraint Induced Language Therapy for Chronic Aphasia

A Phase II, Randomized Blinded Study of the Effects of Transcranial Magnetic Stimulation and Constraint Induced Language Therapy for the Treatment of Chronic Aphasia

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03651700
Enrollment
86
Registered
2018-08-29
Start date
2019-03-28
Completion date
2024-08-31
Last updated
2025-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aphasia

Brief summary

Transcranial Magnetic Stimulation (TMS) has been demonstrated to improve language function in subjects with chronic aphasia in a number of small studies, many of which did not include a control group. Although the treatment appears promising, data to date do not permit an adequate assessment of the utility of the technique. The investigators propose to study the effects of TMS combined with Constraint Induced Language Therapy (CILT) in 75 subjects with chronic aphasia. Subjects will be randomized in a 2:1 ratio to TMS with CILT or sham TMS with CILT. One Hz TMS at 90% motor threshold will be delivered to the right inferior frontal gyrus for 20 minutes in 10 sessions over 2 weeks; language therapy will be provided for one hour immediately after the conclusion of each session of TMS. Change from baseline in the Western Aphasia Battery Aphasia Quotient at 6 months after the end of TMS treatment will serve as the primary outcome measure.

Detailed description

TMS is a technique by which a brief electrical current is induced in brain tissue causing a brief suppression of the excitability of the underlying tissue; the technique, which was introduced in the 1980s and has been extensively used around the world, has been shown to transiently improve or disrupt specific cognitive operations. To achieve this end, a coil is positioned against the subject's head. The delivery of a single pulse begins with the discharge of current from a capacitor into a circular or figure-of-eight coil; this electrical current generates a brief magnetic field of up to 2.2 Tesla. As the pulse of electricity has a rise time of 0.2 ms. and a duration of 1 ms., the magnetic field changes in intensity quite rapidly. Because the magnetic field passes freely through the scalp, skull, and meninges, the flux in the magnetic field induces a small electric field in the brain that transiently alters neural activity. TMS may be delivered in a variety of ways. The investigators propose to use 1 Hz TMS; that is, TMS pulses will be delivered at a frequency of 1/second. This style of TMS is assumed to be inhibitory in that it transiently suppresses the function of the cortex under the coil. Using the figure-of-eight coil to be employed here, TMS is thought to reduce activity in approximately 1 cubic cm. of cortex. Many investigators have employed TMS with a frequency of 1 Hz for periods of 20 minutes and longer; mild behavioral deficits are often present for several minutes in these studies. The baseline phase will consist of 3 sessions, each lasting 1-2 hours depending on the stamina of the subject. The point of the baseline testing is to characterize the subject's language function. To that end, a number of standard language and neuropsychological tasks will be administered. These include the Western Aphasia Battery, Pyramids and Palm Trees test, Figural Fluency Test, word and non-word repetition tasks, the Nicholas and Brookshire Narratives, CILT stimulus naming, and Northwestern Assessment of Verbs and Sentences. Additionally, during the baseline, subjects will undergo MRI of the brain or, if they have a contraindication to MRI, a CAT scan of the head. No contrast will be used. In the treatment phase, there will be 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz TMS at 90% motor threshold will be delivered to the inferior pars triangularis. Each TMS treatment session will be immediately followed by a 60-90 minute session of CILT There will be two 3-month post-treatment visits and two 6-month post-treatment visits in which the full battery of language and cognitive assessments will be repeated. Subjects who are able to undergo MRI scanning will have anatomic and fMRI scans at the first 6-month post-treatment visit. The investigators will pair TMS with CILT which has been shown to have positive outcomes in post-stroke aphasia. CILT invokes use-dependent learning in communicative interactions by requiring spoken output and restricting use of alternative forms of communication, such as gestures. The investigators will use a dual card-matching task modeled after Maher et al. As in the original CILT design, the participant interacts verbally with a conversational partner (here, the speech language pathologist), in turn requesting a card of given description and complying with the partner's request. In this way, the treatment targets both production and comprehension. Moreover, as verbal targets increase in linguistic complexity across the protocol (a ball, throw a ball; Do you have a ball?), a variety of lexical and phrasal structures are targeted. Studies of CILT have reported gains on multiple language behaviors, supporting its broad engagement of the language network.

Interventions

Active TMS will be at 90% motor threshold

DEVICESham TMS

Sham TMS will be administered

BEHAVIORALCILT

60-90 minutes of CILT will be administered during each treatment session

Sponsors

National Institutes of Health (NIH)
CollaboratorNIH
National Institute on Deafness and Other Communication Disorders (NIDCD)
CollaboratorNIH
H. Branch Coslett
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

The individual administering TMS will keep the master file of subject assignments, but all other individuals in contact with the subject or their data will be unaware of group assignment. Participants will not be informed of their assignment to active or sham status.

Intervention model description

Participants will be randomized to either TMS or sham TMS in a 2:1 allocation ratio.

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Clinical evidence and MRI or CT verification of a single left hemisphere stroke with moderate to severe aphasia. * Suffered their stroke at least 6 months prior to their testing * Must be able to understand the nature of the study, and give informed consent

Exclusion criteria

* Multiple strokes (excluding small lacunar strokes) as defined by brain imaging * History of substance abuse * Previous head trauma with loss of consciousness for more than 5 minutes * Psychiatric illness (We note that subjects will be assessed with the 15-item Geriatric Depression scale. Because depression is very difficult to evaluate in aphasic subjects, potential subjects will not be excluded on the basis of the depression score) * Chronic exposure to medications that might be expected to have lasting consequences for the central nervous system (e.g. haloperidol, dopaminergics) * History of or neuropsychological findings suggestive of dementia

Design outcomes

Primary

MeasureTime frameDescription
Change in WAB-AQ6-months post-treatmentThe primary outcome measure will be the change in score on the Western Aphasia Battery Aphasia Quotient (WAB-AQ), a score assessing overall aphasia recovery. Scores can range from 0-100, with higher scores representing better outcomes. 0-25 is very severe, 26-50 is severe, 51-75 is moderate, and 76-above is mild. A score of 93 or higher is considered recovered.

Secondary

MeasureTime frameDescription
Change in Percentage of Items Correct on the PNT6-months post-treatmentThe secondary outcome measure will be change in naming accuracy on the Philadelphia Naming Test (PNT). PNT naming accuracy is measured as a percentage from 0% to 100% with higher percentages meaning better naming ability. The task involves naming 175 pictures of common objects.

Countries

United States

Participant flow

Recruitment details

Participants were recruited from 2019-2024 from the Hospital of the University of Pennsylvania, surrounding Philadelphia area medical centers and aphasia support groups.

Pre-assignment details

A total of 36 participants did not qualify due to medical contraindications (14) or aphasia severity (22). Nine participants dropped out of the study prior to randomization due to safety concerns (1), inability to complete MRI scan (3), lost to follow-up (2), travel concerns (1), no longer interested in participating (2).

Participants by arm

ArmCount
Active TMS
Participants will receive 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz active TMS will be delivered to the inferior pars triangular. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT). Active TMS: Active TMS will be at 90% motor threshold CILT: 60-90 minutes of CILT will be administered during each treatment session
26
Sham TMS
Participants will take part in 10 Sham TMS sessions over 2 consecutive weeks for 20 minutes each day. Sham TMS mimics the sensory experience (look, sound and feel) of active TMS but does not stimulate the brain. Sham TMS will be administered with a sham TMS coil that looks and sounds like the active coil but does not generate a magnetic field. The sham TMS will target the same brain location - left inferior pars triangularis. Each sham TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
15
Total41

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyWithdrawal by Subject10

Baseline characteristics

CharacteristicActive TMSSham TMSTotal
Age, Continuous57.73 years
STANDARD_DEVIATION 10.62
61.67 years
STANDARD_DEVIATION 10.87
59.17 years
STANDARD_DEVIATION 10.88
Ethnicity (NIH/OMB)
Hispanic or Latino
22 Participants0 Participants22 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
3 Participants13 Participants16 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants2 Participants3 Participants
Philadelphia Naming Test, Items Correct110.4 number of items correct
STANDARD_DEVIATION 57
114.0 number of items correct
STANDARD_DEVIATION 42.6
111.7 number of items correct
STANDARD_DEVIATION 51.8
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
2 Participants0 Participants2 Participants
Race (NIH/OMB)
Black or African American
5 Participants4 Participants9 Participants
Race (NIH/OMB)
More than one race
0 Participants1 Participants1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants1 Participants2 Participants
Race (NIH/OMB)
White
18 Participants9 Participants27 Participants
Sex: Female, Male
Female
13 Participants4 Participants17 Participants
Sex: Female, Male
Male
13 Participants11 Participants24 Participants
Western Aphasia Battery (WAB-AQ) Score66.6 score on a scale
STANDARD_DEVIATION 19.9
68.8 score on a scale
STANDARD_DEVIATION 18.5
67.4 score on a scale
STANDARD_DEVIATION 18.7

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 260 / 15
other
Total, other adverse events
13 / 267 / 15
serious
Total, serious adverse events
1 / 261 / 15

Outcome results

Primary

Change in WAB-AQ

The primary outcome measure will be the change in score on the Western Aphasia Battery Aphasia Quotient (WAB-AQ), a score assessing overall aphasia recovery. Scores can range from 0-100, with higher scores representing better outcomes. 0-25 is very severe, 26-50 is severe, 51-75 is moderate, and 76-above is mild. A score of 93 or higher is considered recovered.

Time frame: 6-months post-treatment

ArmMeasureValue (MEAN)Dispersion
Active TMSChange in WAB-AQ3.0 score on a scaleStandard Deviation 3.8
Sham TMSChange in WAB-AQ2.8 score on a scaleStandard Deviation 5.9
p-value: <0.05t-test, 2 sided
Secondary

Change in Percentage of Items Correct on the PNT

The secondary outcome measure will be change in naming accuracy on the Philadelphia Naming Test (PNT). PNT naming accuracy is measured as a percentage from 0% to 100% with higher percentages meaning better naming ability. The task involves naming 175 pictures of common objects.

Time frame: 6-months post-treatment

ArmMeasureValue (MEAN)Dispersion
Active TMSChange in Percentage of Items Correct on the PNT3.4 score on a scaleStandard Deviation 8.9
Sham TMSChange in Percentage of Items Correct on the PNT3.4 score on a scaleStandard Deviation 9.1
p-value: <0.05t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026